Status:
COMPLETED
Levetiracetam for the Treatment of Alcohol Dependence and Anxiety
Lead Sponsor:
New York State Psychiatric Institute
Collaborating Sponsors:
UCB Pharma
Conditions:
Alcoholism
Generalized Anxiety Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if levetiracetam is effective in treating alcohol dependence in patients with anxiety symptoms. The researchers hypothesize that individuals are unable to red...
Detailed Description
Alcohol dependence is frequently associated with anxiety disorders. Treatment studies of individuals suffering from both alcohol dependence and anxiety have been limited. Anti-seizure medications have...
Eligibility Criteria
Inclusion
- Men and women between the ages of 18-65 who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence and a comorbid anxiety disorder, including: panic disorder, social phobia, generalized anxiety disorder, substance-induced anxiety disorder and anxiety disorder, no otherwise specified (NOS).
- Individuals capable of giving informed consent and capable of complying with study procedures.
- Individuals must have clinically significant anxiety.
- Individuals must have current average alcohol use over past 28 days with \> 4 drinking days per week and \>4 standard drinks/drinking day for women and \> 5 standard drinks/drinking day for men.
- Women of child-bearing age will be included provided that they are not pregnant, based on the results of a blood pregnancy test done at the time of screening and agree to use a method of contraception with proven efficacy and not to become pregnant during the study. To confirm this, blood pregnancy tests will be repeated monthly. Women will be provided a full explanation of the potential dangers of pregnancy while on the study. If a woman becomes pregnant the study medication will be discontinued.
- Individual's breathalyzer reading at the time of signing consent must be \< 0.04%.
Exclusion
- Subjects with any current Axis I psychiatric disorder as defined by DSM-IV-Text Revision (DSM-IV-TR) supported by the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) that in the investigator's judgment might require pharmacological intervention, with the exceptions of alcohol dependence and a comorbid anxiety disorder (panic disorder, social phobia, generalized anxiety disorder, substance-induced anxiety disorder and anxiety disorder, NOS). Current diagnoses of post-traumatic stress disorder (PTSD) or obsessive-compulsive disorder are exclusionary.
- Individuals with evidence of moderate to severe alcohol withdrawal that would require pharmacologic intervention.
- Individuals meeting DSM IV criteria for current cocaine or opioid dependence.
- Unstable physical disorders which might make participation hazardous such as uncontrolled hypertension and tachycardia (systolic blood pressure \[SBP\] \> 150 mm Hg, diastolic blood pressure \[DBP\] \> 90 mm Hg, or a sitting quietly heart rate \[HR\] \> 100 bpm), acute hepatitis (patients with chronic mildly elevated transaminase levels ((2-3 x upper limit of normal) are acceptable) or poorly controlled diabetes.
- Patients currently taking prescribed psychotropic medications.
- Patients with a known sensitivity to levetiracetam.
- Individuals who have exhibited suicidal or homicidal behavior within the past two years or have current active suicidal ideation.
- Women who are pregnant or nursing.
- Individuals physiologically dependent on any other drugs (excluding nicotine, caffeine).
- Individuals with a history of a hazardous drinking behavior (e.g., driving while intoxicated convictions, violent crimes committed while intoxicated) will be excluded.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00141115
Start Date
March 1 2004
End Date
January 1 2008
Last Update
April 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032